Literature DB >> 18083204

Delta-9-tetrahydrocannabinol accumulation, metabolism and cell-type-specific adverse effects in aggregating brain cell cultures.

Florianne Monnet-Tschudi1, Arno Hazekamp, Nicolas Perret, Marie-Gabrielle Zurich, Patrice Mangin, Christian Giroud, Paul Honegger.   

Abstract

Despite the widespread use of Cannabis as recreational drug or as medicine, little is known about its toxicity. The accumulation, metabolism and toxicity of THC were analyzed 10 days after a single treatment, and after repeated exposures during 10 days. Mixed-cell aggregate cultures of fetal rat telencephalon were used as in vitro model, as well as aggregates enriched either in neurons or in glial cells. It was found that THC accumulated preferentially in neurons, and that glia-neuron interactions decreased THC accumulation. The quantification of 11-OH-THC and of THC-COOH showed that brain aggregates were capable of THC metabolism. No cell-type difference was found for the metabolite 11-OH-THC, whereas the THC-COOH content was higher in mixed-cell cultures. No cell death was found at THC concentrations of 2 microM in single treatment and of 1 microM and 2 microM in repeated treatments. Neurons, and particularly GABAergic neurons, were most sensitive to THC. Only the GABAergic marker was affected after the single treatment, whereas the GABAergic, cholinergic and astrocytic markers were decreased after the repeated treatments. JWH 015, a CB2 receptor agonist, showed effects similar to THC, whereas ACEA, a CB1 receptor agonist, had no effect. The expression of the cytokine IL-6 was upregulated 48 h after the single treatment with 5 microM of THC or JWH 015, whereas the expression of TNF-alpha remained unchanged. These results suggest that the adverse effects of THC were related either to THC accumulation or to cannabinoid receptor activation and associated with IL-6 upregulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083204     DOI: 10.1016/j.taap.2007.11.007

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  5 in total

1.  Inhibition of monoamine oxidase activity by cannabinoids.

Authors:  Zdenek Fisar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-18       Impact factor: 3.000

2.  The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study.

Authors:  Osama A Abulseoud; Maria Laura Zuccoli; Lifeng Zhang; Allan Barnes; Marilyn A Huestis; Da-Ting Lin
Journal:  Eur Neuropsychopharmacol       Date:  2017-04-26       Impact factor: 4.600

3.  Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users.

Authors:  Camilla Beale; Samantha J Broyd; Yann Chye; Chao Suo; Mark Schira; Peter Galettis; Jennifer H Martin; Murat Yücel; Nadia Solowij
Journal:  Cannabis Cannabinoid Res       Date:  2018-04-01

4.  Subregional Hippocampal Thickness Abnormalities in Older Adults with a History of Heavy Cannabis Use.

Authors:  Alison C Burggren; Prabha Siddarth; Zanjbeel Mahmood; Edythe D London; Theresa M Harrison; David A Merrill; Gary W Small; Susan Y Bookheimer
Journal:  Cannabis Cannabinoid Res       Date:  2018-12-10

5.  Sex and dependence related neuroanatomical differences in regular cannabis users: findings from the ENIGMA Addiction Working Group.

Authors:  Maria Gloria Rossetti; Scott Mackey; Praveetha Patalay; Nicholas B Allen; Albert Batalla; Marcella Bellani; Yann Chye; Patricia Conrod; Janna Cousijn; Hugh Garavan; Anna E Goudriaan; Robert Hester; Rocio Martin-Santos; Nadia Solowij; Chao Suo; Paul M Thompson; Murat Yücel; Paolo Brambilla; Valentina Lorenzetti
Journal:  Transl Psychiatry       Date:  2021-05-06       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.